Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
life sciences
national blog main
biotech
boston blog main
boston top stories
drugs
national top stories
new york blog main
san diego blog main
san francisco blog main
akcea therapeutics
anylam pharmaceuticals
apps
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
bio
bluebird bio
boston
cannabidiol
cardiomyopathy
disease
dravet syndrome
duchenne muscular dystrophy
dyne therapeutics
electronic medical records
epidiolex
facioscapulohumeral muscular dystrophy
fda
fen-phen
fenfluramine
first round capital
flatiron health
funding
fundings & exits
gene therapy
gw pharmaceuticals
health
What
ago
4
×
rare
4
×
data
drug
approved
battle
disease
diseases
fda
genetic
medicines
sets
akcea
alnylam
amyloidosis
app
attacks
attr
available
biotechs
called
cannabis
caused
chat
competitor
considering
debilitating
derivative
diagnosed
dyne
ear
early
epilepsy
expect
expected
experimental
eyes
faber
form
founder
Language
unset
Current search:
rare
×
ago
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@techcrunch.com
5 years ago
RDMD attacks rare diseases with data mined from health records
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug